These data illustrate that the repression signature of CDK4/6 inhibition has potent prognostic activity, suggesting that treatment with CDK4/6 inhibition would be associated with a switch to a form of ER+ breast cancer with a generally improved prognosis. Here, ESR1 is linked to breast carcinoma.